Abstract 246P
Background
Despite various awareness programmes and strict regulations for consumption of tobacco and alcohol, the incidence of oral cavity cancer is increasing in low and middle income countries. We have reported here clinico-epidemiological profile of 343 oral cavity cancer patients. Although, treatment guidelines exist, treatment failure is seen in more than 50% of patients.
Methods
We retrospectively analysed the data of 343 oral cavity cancer patients who reported to our department during 2010-2015. Detailed history and clinical examination followed by requisite investigations were done and treatment was given as per the existent guidelines.
Results
Out of 343 patients, 283 (82.5%) were males while 60 (17.4%) were females with a male: female ratio of 4.7:1. The mean and median age for the cohort was 46.2 yrs and 45 yrs, respectively. More patients presented in the age group of 31-40 yrs (29.4%) and 41-50 yrs (27.4%). The youngest patient was 21 yrs while the oldest was 85 yrs. Tongue was the most common site of involvement followed by buccal mucosa. Histopathologically, tumours with moderate differentiation were most frequent followed by well differentiated. Approximately, 60% patients underwent surgery with or without adjuvant radiation. Remaining 40% cases, for whom surgery could not be done, received definitive radiation. Overall, however, 40% of cases had treatment failure despite aggressive multimodality treatment with local recurrence observed in more than half. Locoregional recurrence occurred in 19.1% while disease metastasized to distant areas in 8.8% cases.
Conclusions
Our study provided a clinico-epidemiological profile and failure rates of patients having oral cavity cancers in North India. We have tried to study various risk factors associated with the disease. Significant number of patients presents very late in our setting and so failure rates are unacceptably high. Hence, there is a need to study various therapies for effective management without adding any significant financial burden on patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03